Sleepiz AG

Sleepiz AG is a Swiss company specializing in innovative sleep and vital parameter monitoring solutions. Their flagship product, the Sleepiz One+, enables precise, contact-free monitoring of sleep patterns and vital signs. Sleepiz AG, founded in 2018 in Zurich, Switzerland, focuses on developing advanced medical devices for sleep monitoring. The company has successfully closed 6 funding deals, with the latest being a Series A round in March 2022, raising CHF 1.

8 million, bringing the total amount raised to CHF 1. 8 million. The founding team includes Marc Rullan, Max Sieghold, and CEO Soumya Dash. Sleepiz AG specializes in advanced sleep and vital parameter monitoring solutions, primarily through its core product, the Sleepiz One+.

This Class IIa, CE-marked medical device employs radar technology to facilitate contact-free monitoring of patients' sleep patterns and vital signs, including breathing patterns and heartbeats, with sub-millimeter accuracy. The Sleepiz One+ is designed for ease of use, allowing for quick installation and seamless data transmission via a cellular module, making it suitable for a broad demographic of users aged 20 to over 80 years old. The technology is particularly beneficial for home monitoring of respiratory diseases, immunology, and sleep disorders, thus offering significant advantages over traditional polysomnography (PSG) methods, which are costly and time-consuming. Sleepiz's products have been validated through clinical trials in Switzerland and Germany and are marketed primarily in European markets, expanding to other geographical regions where demand for remote patient monitoring solutions exists.

The revenue model for Sleepiz AG is primarily based on the sale of its flagship product, the Sleepiz One+, to healthcare providers, researchers, and clinical trial participants. Transactions are structured as direct sales to hospitals and clinics, as well as partnerships with healthcare organizations that utilize the Sleepiz technology for ongoing remote patient monitoring. Clients benefit from continuous monitoring capabilities, with users typically recording substantial amounts of data over extended periods, often leading to multiple successful recordings in a month. The company offers various options for integrating additional Bluetooth devices, such as SpO2 sensors, enhancing the service's value and potential revenue opportunities.

The pricing structure accommodates both one-time purchases and potential subscription models for ongoing data services, ensuring a steady revenue stream from its diverse client base. In March 2022, Sleepiz AG raised CHF 1. 8 million in Series A funding, part of a larger CHF 6. 2 million round.

The company plans to utilize this funding to further roll out its monitor specifically aimed at diagnosing sleep disorders. Additionally, Sleepiz AG is focused on expanding its market presence beyond Europe into regions where the demand for remote patient monitoring is increasing, although specific targets and timelines have not been disclosed.